Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cholizyme is a digestive enzyme combination marketed by Lancet Pharmaceuticals, an Indian branded generic pharmaceutical company. Formulated as a syrup, it typically contains fungal diastase and pepsin. Fungal diastase is an amylolytic enzyme derived from fungal sources (such as *Aspergillus oryzae*) that catalyzes the breakdown of starch and complex carbohydrates into simpler sugars, thereby facilitating carbohydrate digestion. Pepsin is a proteolytic enzyme that assists in the degradation of proteins into smaller peptides and amino acids. Together, these enzymes supplement the body's natural digestive secretions and are indicated for the management of functional dyspepsia, flatulence, indigestion, and loss of appetite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cholizyme.